Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia-a propensity score analysis

Koji Sasaki, Hagop Kantarjian, Elias Jabbour, Farhad Ravandi, Koichi Takahashi, Marina Konopleva, Gautam Borthakur, Guillermo Garcia-Manero, William Wierda, Naval Daver, Preetesh Jain, Toshihisa Satta, Sherry Pierce, May Beth Rios, Jorge E. Cortes

Research output: Contribution to journalLetterpeer-review

3 Scopus citations
Original languageEnglish (US)
Pages (from-to)e324-e327
JournalHaematologica
Volume101
Issue number8
DOIs
StatePublished - Jul 31 2016
Externally publishedYes

Keywords

  • Chronic myeloid leukemia
  • Dasatinib
  • High-dose imatinib
  • Nilotinib

ASJC Scopus subject areas

  • Hematology

Cite this